Family Study Designs Informed by Tumor Heterogeneity and Multi-Cancer Pleiotropies: The Power of the Utah Population Database

Abstract

Background: Previously, family-based designs and high-risk pedigrees have illustrated value for the discovery of highand intermediate-risk germline breast cancer susceptibility genes. However, genetic heterogeneity is a major obstacle hindering progress. New strategies and analytic approaches will be necessary to make further advances. One opportunity with the potential to address heterogeneity via improved characterization of disease is the growing availability of multisource databases. Specific to advances involving family-based designs are resources that include family structure, such as the Utah Population Database (UPDB). To illustrate the broad utility and potential power of multisource databases, we describe two different novel family-based approaches to reduce heterogeneity in the UPDB.Methods: Our first approach focuses on using pedigree-informed breast tumor phenotypes in gene mapping. Our second approach focuses on the identification of families with similar pleiotropies. We use a novel network-inspired clustering technique to explore multi-cancer signatures for high-risk breast cancer families.Results: Our first approach identifies a genome-wide significant breast cancer locus at 2q13 [P ¼ 1.6 Â 10 À8 , logarithm of the odds (LOD) equivalent 6.64]. In the region, IL1A and IL1B are of particular interest, key cytokine genes involved in inflammation. Our second approach identifies five multi-cancer risk patterns. These clusters include expected coaggregations (such as breast cancer with prostate cancer, ovarian cancer, and melanoma), and also identify novel patterns, including coaggregation with uterine, thyroid, and bladder cancers.Conclusions: Our results suggest pedigree-informed tumor phenotypes can map genes for breast cancer, and that various different cancer pleiotropies exist for high-risk breast cancer pedigrees.Impact: Both methods illustrate the potential for decreasing etiologic heterogeneity that large, population-based multisource databases can provide.See all articles in this CEBP Focus section, "Modernizing Population Science."

Charting the life course: Emerging opportunities to advance scientific approaches using life course research

“…ML methods, therefore, can play an important role in discovering unknown predictors of disease as well as refining phenotypic definitions of disease. Pattern identification, dimension reduction, and phenotypic definitions can be used to hone the search for causal mechanisms [45,47]. Methods embracing complexity science have the potential to identify factors having the largest impact on disease risk, the importance of duration and dose of exposure, periods across the lifespan that might be most amenable to intervention, the dynamic nature of risk, and moderating factors that should be considered.…”

“…ML identifies patterns that explain the data available in both supervised (trained on an outcome) or unsupervised (trained to find a pattern) approaches. Pattern discovery algorithms are generally unsupervised, and can be used to refine our definition of phenotype [47,[47][48][49][50]. Algorithms are developed to seek out variables and combinations of variables to predict outcomes.…”

Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicates CXCR4 in inherited risk

“…This identified two germline CNVs: a mutation at 13q involving DLEU7 and a gain at 6p including IRF4. Each was shared by a single CLL sib-pair [13] . These findings have yet to be replicated.…”

Deep transcriptome profiling of multiple myeloma with quantitative measures using the SPECTRA approach

“…When the framework was implemented in an external dataset of tumors from high-risk breast cancer pedigrees, these quantitative PCA variables as phenotypes proved superior to the standard PAM50 subtypes for gene mapping. 1,25 Further, when implemented in a second external clinical trial dataset, PCA variables were able to predict response to paclitaxel. 24 Here, we extend the approach to the whole transcriptome.…”